Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence

Cancer Research

Volumn 74, Issue 12, 2014, Pages 3228-3237

  Long, Qi ^b   Xu, Jianpeng ^a   Osunkoya, Adeboye O ^a,b,c   Sannigrahi, Soma ^a   Johnson, Brent A ^b   Zhou, Wei ^a,b   Gillespie, Theresa ^a,b   Park, Jong Y ^d   Nam, Robert K ^e,f   Sugar, Linda ^e,f   Stanimirovic, Aleksandra ^e,f   Seth, Arun K ^e,f   Petros, John A ^a,b,c   Moreno, Carlos S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GERANYLTRANSFERASE; MAX PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SIRTUIN 1; SOMATOMEDIN BINDING PROTEIN 3; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BTG2 GENE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE PROGRESSION; CELL HYPOXIA; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPITHELIAL MESENCHYMAL TRANSITION; FDPS GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION AND TRANSLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IGFBP3 GENE; MAJOR CLINICAL STUDY; MALE; MXI1 GENE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; RNA SEQUENCE; SIGNAL TRANSDUCTION; SIRT1 GENE; STEROID METABOLISM; TRANSCRIPTOMICS; TRANSLATION REGULATION;

ADULT; FIXATIVES; FORMALDEHYDE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903466463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2699     Document Type: Article

References (45)

1. American Cancer Society [Internet]. Cancer facts and figures 2013: American Cancer Society; [updated 2013; cited 2013]. Available from: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-2013.
2. Gleason DF. Histologic grading of prostate cancer: a perspective.Hum Pathol 1992;23:273-9.
3. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
4. Berg KD, Roder MA, Brasso K, Vainer B, Iversen P. Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy. Scand J Urol 2014;48:168-76.
5. Ro YK, Lee S, Jeong CW, Hong SK, Byun SS, Lee SE. Biochemical recurrence in Gleason score 7 prostate cancer in Korean men: significance of the primary Gleason grade. Korean J Urol 2012;53:826-9.
6. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001;25:657-60. (Pubitemid 32423365)
7. Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, et al. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol 2011;179:46-54.
8. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55.
9. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-5. (Pubitemid 350249347)
10. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, Bouzyk M, et al. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 2008;44:417-23. (Pubitemid 351498195)
11. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-11.
12. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010;28:511-5.
13. www.ingenuity.com [Internet]. Ingenuity Knowledgebase [updated 2013; cited 2013]. Available from: http://www.ingenuity.com/.
14. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010;11:R106.
15. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997;16:385-95. (Pubitemid 27073009)
16. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J 2010;52:70-84.
17. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
18. Uno H, Tian L, Cai T, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med 2013;32:2430-42.
19. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
20. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9. (Pubitemid 47206938)
21. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13:519-28. (Pubitemid 351763901)
22. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80. (Pubitemid 351380107)
23. Lavery HJ, Droller MJ. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol 2012;188:1667-75.
24. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, et al. Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis 2001;22:1271-9. (Pubitemid 32737344)
25. Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate 2008;68:296-305. (Pubitemid 351273059)
26. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005;24:188-98. (Pubitemid 40143878)
27. McCabe CD, Spyropoulos DD, Martin D, Moreno CS. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008;68:1988-96. (Pubitemid 351416586)
28. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, Rohr LR, et al. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 1998;22:295-304. (Pubitemid 28304520)
29. Todenhofer T, Hennenlotter J, Kuhs U, Gerber V, Gakis G, Vogel U, et al. Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression? World J Urol 2013;31:345-50.
30. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012;31:4619-29.
31. Powell MJ, Casimiro MC, Cordon-Cardo C, He X, Yeow WS, Wang C, et al. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res 2011;71:964-75.
32. Noetzel E, Rose M, Sevinc E, Hilgers RD, Hartmann A, Naami A, et al. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. Oncogene 2010;29:4814-25.
33. Papadimitriou E, Mikelis C, Lampropoulou E, Koutsioumpa M, Theochari K, Tsirmoula S, et al. Roles of pleiotrophin in tumor growth and angiogenesis. Eur Cytokine Netw 2009;20:180-90.
34. Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 2002;4:95-105. (Pubitemid 34141474)
35. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, et al. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 2005;4:1285-94.
36. Szlufcik K, Bultynck G, Callewaert G, Missiaen L, Parys JB, De Smedt H. The suppressor domain of inositol 1,4,5-trisphosphate receptor plays an essential role in the protection against apoptosis. Cell Calcium 2006;39:325-36. (Pubitemid 43286325)
37. Cortes-Sempere M, de Miguel MP, Pernia O, Rodriguez C, de Castro Carpeno J, Nistal M, et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene 2013;32:1274-83.
38. Sorokin AV, Chen J. MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells. Oncogene 2013;32:3130-8.
39. Kim J, Park RY, Chen JK, Kim J, Jeong S, Ohn T. Splicing factor SRSF3 represses the translation of programmed cell death 4 mRNA by associating with the 5′-UTR region. Cell Death Differ 2014;21:481-90.
40. Fang L, Hemion C, Goldblum D, Meyer P, Orgul S, Frank S, et al. Inactivation of MARCH5 prevents mitochondrial fragmentation and interferes with cell death in a neuronal cell model. PLoS One 2012;7:e52637.
41. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfor K, et al. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009;5:e1000719.
42. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999;398:824-8.
43. Wang Q, Sharma D, Ren Y, Fondell JD. A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem 2002;277:42852-8. (Pubitemid 35285661)
44. Rieger ME, Sims AH, Coats ER, Clarke RB, Briegel KJ. The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol 2010;30:4267-79.
45. Prokopec SD, Watson JD, Waggott DM, Smith AB, Wu AH, Okey AB, et al. Systematic evaluation of medium-throughput mRNA abundance platforms. RNA 2013;19:51-62.